On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
EMP-012 utilizes a novel mechanism that targets a specific inflammatory pathway, allowing for treatment that is independent of baseline type 2 inflammation, smoking, or co-morbid conditions. Supported by extensive genetic data, this approach could benefit patients with non-type 2 inflammation, a group with limited treatment options. EMP-012's enhanced potency and longer dosing interval, derived from Empirico’s proprietary siRNA technology, complement GSK’s existing COPD programs, including long-acting biologics. Additionally, EMP-012 offers GSK the flexibility to explore combination therapies within its COPD portfolio.
The agreement grants GSK full worldwide development and commercial rights to EMP-012. Empirico will continue to lead the clinical development of EMP-012 through the completion of the ongoing Phase 1 clinical trial, following which GSK will assume responsibility for worldwide development, regulatory filings, and commercialization. GSK will pay an $85 million upfront payment and up to $660 million in milestone payments, along with royalties on net sales worldwide.
The Wilson Sonsini team that advised Empirico on the transaction includes:
Technology Transactions
David Pirko
Adam Kaldor
Alex DeLaney
Patents and Innovations
Matt Bresnahan
Sean Reed
Corporate
Jason Skolnik
Brandon Shaw
For more information, please see GSK's and Empirico's joint news release. Additional coverage can be found on Fierce Biotech.
